Pulmonary Drugs Market Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
The pulmonary drugs market is a
significant part of the pharmaceutical industry, with a global market size
projected to reach USD 60.1 billion by 2026, according to a report by Grand
View Research. This market comprises drugs used in the treatment of respiratory
diseases, including asthma, chronic obstructive pulmonary disease (COPD),
pulmonary arterial hypertension (PAH), and cystic fibrosis. The increasing
prevalence of these diseases, coupled with the rising geriatric population, is
expected to drive the growth of this market in the coming years.
Asthma is a chronic respiratory
disease that affects the airways in the lungs, causing them to narrow and
making it difficult to breathe. According to the World Health Organization,
asthma affects around 235 million people worldwide. The treatment of asthma
primarily involves the use of inhaled corticosteroids, which reduce
inflammation in the airways, and bronchodilators, which relax the muscles
around the airways. The Pulmonary
Drugs Market was valued at USD 22.2 billion in 2020, according
to a report by Market Research Future.
COPD is a group of lung diseases
that cause breathing difficulties, including chronic bronchitis and emphysema.
The primary cause of COPD is smoking, but it can also be caused by exposure to
air pollution, dust, and chemicals. According to the Global Initiative for
Chronic Obstructive Lung Disease, COPD is the third leading cause of death worldwide
Pulmonary Drugs Market, with over
251 million cases reported in 2016. The treatment of COPD involves the use of
bronchodilators, corticosteroids, and antibiotics. The global market for COPD
drugs was valued at USD 14.5 billion in 2020.
PAH is a rare but severe
condition that affects the blood vessels in the lungs, causing high blood
pressure in the pulmonary arteries. PAH can lead to heart failure if left
untreated. The primary cause of PAH is unknown, but it can be associated with
other conditions such as connective tissue diseases and congenital heart
disease. The treatment of PAH involves the use of vasodilators, which relax the
blood vessels in the lungs, and endothelin receptor antagonists, which block
the action of endothelin, a peptide that causes blood vessels to constrict. The
global market for PAH drugs was valued at USD 6.9 billion in 2020.
Comments
Post a Comment